Double Blind Positive Control – 2.5% PAAG Hydrogel

Reasons for performing the study:

Intra-articular administration of a 2.5% polyacrylamide hydrogel (PAAG- Arthramid Vet) is shown to reduce or abolish lameness in distal interphalangeal (coffin) and metacarpo/ metatarso- phalangeal (fetlock) joints in horses undertaking equestrian disciplines. To date there have been no studies evaluating its’ efficacy in inter-carpal (knee) joints of racehorses conducted at an acceptable standard.

Objectives:

To investigate the efficacy of a 2.5% PAAG (Arthramid Vet) in the management of inter-carpal joint lameness in racing Thoroughbreds.

Study design: 

Prospective double-blinded positive-control study.

Methods:

33 flat-racing Thoroughbreds in full training at a single training facility with lameness (AAEP 1-3/5) localised to the inter-carpal joint by intra-articular analgesia and radiological assessment were enrolled. Horses were randomly allocated to be treated intra-articularly with either 2ml of a 2.5% polyacrylamide hydrogel, 12mg of triamcinolone acetonide or 20mg of sodium hyaluron (followed by 2 further intravenous treatments of 40mg, at weekly intervals), by the treating veterinarian. All horses were rested for 48 hours’ post-treatment and then re-entered an unaltered training regime.

Subsequent examinations at 2, 4, and 6 weeks were performed by the blinded examining veterinarian for all groups. Horses treated with the 2.5% PAAG (Arthramid Vet) were monitored through to 12 weeks for reoccurrence of lameness in the treated joint.

Results:

Compared to horses that received triamcinolone acetonide or sodium hyaluron, horses treated with 2.5% PAAG (Arthramid Vet) showed a greater chance of resolution of lameness, joint effusion and reaction to passive flexion at four (p<0.05) and six (p<0.05) weeks, with no difference seen between groups at 2 weeks. There was no significant difference between the triamcinolone acetonide and sodium hyaluronate groups at any time point. Two-thirds of horses treated with the 2.5% PAAG hydrogel were still lame-free at 12 weeks. 

Conclusions:

This study indicates that a 2.5% PAAG (Arthramid Vet) hydrogel can be used in the management of inter-carpal joint lameness in flat-racing Thoroughbreds and was superior to and longer lasting than both Triamcinalone and Hyaluronic Acid. A reduction in joint effusion and reaction to passive flexion aligns with the proposed mode of action of Arthramid Vet.

Table 1: Pre-admission variables per treatment group. There was no statistically significant different between treatment groups.
 

PAAG

TA

HA

Number

12

11

10

Age: range (mean)

2-5 (3.08)

2-4 (3)

2-6 (2.8)

Sprinter (%)

5 (42)

5 (45)

4 (40)

Miler (%)

5 (42)

4 (36)

4 (40)

Stayer (%)

2 (16)

2 (19)

2 (20)

Lameness range (mean)

1-3 (1.67)

1-4 (2.18)

1-3 (1.8)

Effusion range (mean)

0-2 (0.5)

0-1 (0.1)

0-2 (0.2)

Reaction to flexion range (mean)

0-2 (0.67)

 0-2 (0.54)

0-2(0.6)

Radiological score range (mean)

0-2 (0.5)

0-2 (0.63)

0-2 (0.6)

Lameness Outcome By Treatment At 6 Weeks
Joint Effusion Outcome By Treatment At 6 Weeks
Reaction To passive Flexion Outcome By Treatment At 6 Weeks

Arthramid Vet 2.5% PAAG

Precision Medicine

  • Studies show up to 82.5% of horses respond with a successful resolution of joint lameness.
  • Meets Animal Welfare Concerns; Arthramid Vet is not simply a lubricant or painkiller. Its unique biomedical technology that helps heal and restore the joint to healthy function.
  • Made to Last; When compared to traditional treatments for joint lameness, research shows that Arthramid Vet is better and lasts longer with proven efficacy for up to 1- 2 years.
  • One of A Kind; Arthramid Vet's unique and patented IL-X Cross-Linking technology makes it the safest and most effective 2.5% Polyacrylamide (PAAG) Hydrogel available.
  • Addresses Equine Welfare Concerns
  • Long-lasting Clinical Effects of Treatment
  • 82.5% Successful Resolution of Joint Lameness

Get In Touch

Contact Us

First Name:
Last Name:
Your Email:
Phone:
Business Name:
Subject:

IMS Vet
Phone +64 (09) 8013 253
sales@imsvet.com

Arthramid Vet Australia

Registered in Australia to: IMS Vet Pty Limited, 1953 Grampian's Road, Fyans Creek, Victoria 3381. Registered pursuant to the APVMA Number 86728/0320. See www.apvma.gov.au for registration conditions.

Address for Service:
IMSVet, PO Box 1083, Cambridge 3450, New Zealand
Phone +61 (0272) 018 497
sales@imsvet.com